# Congruence Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/congruence-therapeutics

- Industry: Biotechnology
- Headquarters: Montreal, Canada
- Website: www.congruencetx.com
- Total disclosed funding: $96M
- Latest round: Series B (Sep 4, 2025)
- Investors on record: 9

## About

Based in Montreal, Canada, and founded in 2021, Congruence Therapeutics Inc. operates as a biotechnology company that develops and discovers small molecules for protein misfolding diseases. Congruence Therapeutics Inc. is an inventor of a pharmacological stabilizer for the treatment of rare diseases. Additionally, the company deploys an in silico platform that enables the design of an established class of small molecules, assisting researchers in the design of biomolecules for protein misfolding diseases.

## Funding rounds

- Series B, Sep 4, 2025, $32M — OrbiMed Advisors, BDC Capital, Investment Quebec, Driehaus Capital Management, Alexandria Capital, SilverArc Capital, Amplitude, Fonds de solidarite FTQ, Lumira Ventures
- Series A, Mar 6, 2023, $15M — OrbiMed Advisors, BDC Capital, Investment Quebec, SilverArc Capital, Amplitude, Fonds de solidarite FTQ
- Series A, Feb 8, 2022, $50M — OrbiMed Advisors, Investment Quebec, Driehaus Capital Management, Amplitude, Fonds de solidarite FTQ, Lumira Ventures

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Investment Quebec (https://capitalatlas.ai/funds/investment-quebec) — Series A, Series B
- Driehaus Capital Management (https://capitalatlas.ai/funds/driehaus-capital-management) — Series A, Series B
- Amplitude (https://capitalatlas.ai/funds/amplitude) — Series A, Series B
- Fonds de solidarite FTQ (https://capitalatlas.ai/funds/fonds-de-solidarite-ftq) — Series A, Series B
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series A, Series B
- BDC Capital (https://capitalatlas.ai/funds/bdc-capital) — Series A, Series B
- SilverArc Capital (https://capitalatlas.ai/funds/silverarc-capital) — Series A, Series B
- Alexandria Capital — Series B